Trial Profile
Investigation of effective treatment of nocturnal hypertension in diabetes.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 04 Apr 2017
Price :
$35
*
At a glance
- Drugs Losartan/hydrochlorothiazide (Primary) ; Angiotensin receptor antagonists; Calcium channel antagonists
- Indications Essential hypertension
- Focus Therapeutic Use
- 02 Apr 2017 Status changed from recruiting to discontinued.
- 17 Sep 2009 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
- 11 Jul 2009 New trial record